GSK Biologicals' Fluarix™ — Competitive Intelligence Brief

GSK Biologicals' Fluarix™ (GSK Biologicals' Fluarix™) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inactivated influenza vaccine. Area: Immunology / Infectious Disease.

phase 3 Inactivated influenza vaccine Immunology / Infectious Disease Biologic

Target snapshot

GSK Biologicals' Fluarix™ (GSK Biologicals' Fluarix™) — GlaxoSmithKline. Fluarix is an inactivated influenza vaccine that stimulates the immune system to produce antibodies against seasonal influenza virus strains.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
GSK Biologicals' Fluarix™ TARGET	GSK Biologicals' Fluarix™	GlaxoSmithKline	phase 3	Inactivated influenza vaccine
CSL Limited Influenza Virus Vaccine	CSL Limited Influenza Virus Vaccine	Seqirus	marketed	inactivated influenza vaccine
SD Fluzone Vaccine	SD Fluzone Vaccine	Insight Therapeutics, LLC	marketed	inactivated influenza vaccine
Influenza Fluzone vaccine	Influenza Fluzone vaccine	La Jolla Institute for Immunology	marketed	inactivated influenza vaccine
Seasonal trivalent influenza vaccine, Fluarix	Seasonal trivalent influenza vaccine, Fluarix	Center for Disease Prevention and Control of Beijing Military Region	marketed	inactivated influenza vaccine
CSL Influenza Vaccine	CSL Influenza Vaccine	Seqirus	marketed	inactivated influenza vaccine
SD-QIV	SD-QIV	McGill University Health Centre/Research Institute of the McGill University Health Centre	marketed	Inactivated influenza vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inactivated influenza vaccine class)

1. GlaxoSmithKline · 16 drugs in this class
2. Seqirus · 5 drugs in this class
3. Sanofi Pasteur, a Sanofi Company · 5 drugs in this class
4. Green Cross Corporation · 4 drugs in this class
5. Novartis · 2 drugs in this class
6. SK Chemicals Co., Ltd. · 2 drugs in this class
7. Sanofi · 2 drugs in this class
8. Hospital Israelita Albert Einstein · 2 drugs in this class
9. McGill University Health Centre/Research Institute of the McGill University Health Centre · 2 drugs in this class
10. Il-Yang Pharm. Co., Ltd. · 2 drugs in this class